First Trust Advisors LP boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 358.1% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 279,121 shares of the medical device company’s stock after acquiring an additional 218,188 shares during the period. First Trust Advisors LP owned about 0.31% of DexCom worth $41,656,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Gradient Investments LLC acquired a new position in DexCom during the second quarter worth $25,000. Virtus ETF Advisers LLC acquired a new stake in shares of DexCom in the second quarter valued at about $29,000. CSat Investment Advisory L.P. acquired a new stake in shares of DexCom in the second quarter valued at about $31,000. Steward Partners Investment Advisory LLC acquired a new stake in shares of DexCom in the second quarter valued at about $31,000. Finally, Wealthcare Advisory Partners LLC acquired a new stake in shares of DexCom in the second quarter valued at about $37,000. Institutional investors own 96.55% of the company’s stock.

Shares of DXCM traded up $0.15 during mid-day trading on Tuesday, reaching $205.83. The stock had a trading volume of 26,218 shares, compared to its average volume of 1,148,939. The company has a debt-to-equity ratio of 1.41, a current ratio of 5.63 and a quick ratio of 5.26. DexCom, Inc. has a 52-week low of $105.05 and a 52-week high of $205.93. The business’s fifty day moving average is $157.33 and its 200 day moving average is $147.12. The firm has a market cap of $18.13 billion, a price-to-earnings ratio of 684.50 and a beta of 0.64.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Wednesday, November 6th. The medical device company reported $0.65 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.20 by $0.45. DexCom had a negative net margin of 12.68% and a positive return on equity of 16.16%. The firm had revenue of $396.30 million during the quarter, compared to analyst estimates of $348.99 million. During the same quarter in the prior year, the firm posted $0.17 earnings per share. DexCom’s quarterly revenue was up 48.6% on a year-over-year basis. As a group, sell-side analysts anticipate that DexCom, Inc. will post 1.41 EPS for the current fiscal year.

In related news, EVP Steven Robert Pacelli sold 1,532 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $155.47, for a total value of $238,180.04. Following the completion of the sale, the executive vice president now owns 66,821 shares of the company’s stock, valued at $10,388,660.87. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Nicholas Augustinos sold 1,208 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $145.49, for a total transaction of $175,751.92. The disclosure for this sale can be found here. Insiders sold 105,222 shares of company stock valued at $16,407,406 in the last three months. 0.88% of the stock is currently owned by insiders.

A number of equities research analysts have recently commented on DXCM shares. Piper Jaffray Companies increased their target price on shares of DexCom from $182.00 to $200.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $215.00 target price (up from $190.00) on shares of DexCom in a research report on Thursday, November 7th. Jefferies Financial Group increased their target price on shares of DexCom from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Thursday, November 7th. Raymond James increased their target price on shares of DexCom from $172.00 to $189.00 and gave the company an “outperform” rating in a research report on Thursday, November 7th. Finally, Morgan Stanley increased their target price on shares of DexCom from $175.00 to $202.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. DexCom presently has a consensus rating of “Buy” and a consensus price target of $190.67.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Further Reading: What moving averages are used to define a golden cross?

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.